January 2007 Volume 3, Issue 1
Volume 3, Issue 1 | January 2007
January 2007
In this Issue
Automation & Instrumentation

DMetrix, Definiens to provide high-throughput image capture, analysis
DMetrix Inc., the developer of ultra-rapid, array-microscope digital imaging systems, announced that it has formed a partnership with Definiens AG, based in Munich, Germany. Their goal is to accelerate the development of a system that will provide completely automated digital pathology
DMetrix, Definiens to provide high-throughput image capture, automated analysis
TUCSON, Ariz.—DMetrix Inc., the developer of ultra-rapid, array-microscope digital imaging systems, announced that it has formed a partnership with Definiens AG, based in Munich, Germany. Their goal is to accelerate the development of a system that will provide completely automated digital pathology.
Automating Digital Pathology
DMetrix, Definiens to provide high-throughput image capture and automated analysis
One for the tools: PerkinElmer acquires Evotec
Looking to fill in its line of equipment focused on cell-based assays, Perkin Elmer Inc. announced late last year the acquisition of Evotec AG’s subsidiary Evotec Technologies.
Two for the cells: PerkinElmer buys Euroscreen
Following close on the heels of the announcement that it had acquired new instrumentation and software lines through its buyout of Evotec Technologeis, PerkinElmer announced in late December its intent to also acquire Euroscreen Products S.A.
A license to amplify
Sigma-aldrich secures whole transcriptome amplification technology from Rubicon Genomics
Pocket change: Thermo Fisher buys Cohesive for $25 million
Thermo Fisher Scientific Inc. announced the acquisition of Massachusetts-based Cohesive Technologies Inc., a manufacturer of advanced TLX turbulent flow sample extraction and liquid chromatography products.Research & Development

Enanta pockets $57 million in HCV deal with Abbott
WATERTOWN, Mass.—Enanta Pharmaceuticals and Abbott announced in early December a worldwide agreement for the research, development and commercialization of hepatitis C virus (HCV) NS3 and NS3/4A protease inhibitors.
A validating HCV deal
Enanta pockets $57 million upfront in protease inhibitor deal with Abbott
Paying the toll for vaccines
Idera strikes multimillion-dollar deal for use of Toll-like Receptor agonists in Merck vaccines.
Heart-felt matchup
Cytokinetics and Amgen to research and market cardiac contractility drugsGenomics & Proteomics

Q&A: Troy Moore, CTO Open Biosystems
Inspired by the open source software movement and the open sharing of knowledge and discoveries that occurred during the Human Genome Project, Brian Pollock and Troy Moore founded Huntsville, Ala.-based Open Biosystems in 2001
Q&A: Troy Moore, CTO, Open Biosystems
Inspired by the open source software movement and the open sharing of knowledge and discoveries that occurred during the Human Genome Project, Brian Pollock and Troy Moore founded Huntsville, Ala.-based Open Biosystems in 2001
Genetics tailored to fit
Invitrogen to become exclusive worldwide distributor of Blue Heron\'s custom gene services
Partnering up for sample prep
Pressure BioSciences enters three-month \"proof-of-concept\" collaboration with Alfa Wassermann
Intrexon buys majority stake in RheoGene
Merger creates a biotech firm targeting gene-based therapiesInformatics

Almac licenses MetaCore for cancer-oriented microarrays and genomic services
CRAIGAVON, Northern Ireland—Almac Group announced recently a decision to license St. Joseph, Mich.-based GeneGo’s flagship data mining suite, MetaCore, for use by its Almac Diagnostics division.
Getting to the core of the matter
Almac licenses MetaCore for cancer-oriented microarrays and genomic services
Getting under your skin
New Entelos platform gives in silico peek at dermatological efficacy and events
Legitimizing license
Health Discovery Corp. grants SVM patent license to Pfizer
Q&A: Neil Kipling, fouder and CEO IDBS
Guiildford, U.K.-based software developer IDBS is probably best known in the industry for its suite of drug discovery software products called ActivityBase.
Max Planck expands access to Elsevier portfolio
MUNICH, Germany—Having operated on a decentralized basis with their library information services until now, the Max Planck Society recently entered into an agreement with Amsterdam-based scientific publisher Elsevier.

Subscribe to our eNewsletters
Stay connected with all of the latest from Drug Discovery News.
Subscribe